AbbVie Deals With Disco for Cancer Therapies

AbbVie has agreed to pay up to 2.54 billion dollars to partner with Germany-based Disco Pharmaceuticals. The deal focuses on developing next-generation bispecific cancer therapies for solid tumors. Disco will handle early research while AbbVie retains exclusive licensing options.

Xurve View
Insights:
The logo of Abbvie pharmaceutical company is seen on their plant in the IDA (Industrial Development Agency) estate, in Carrigtwohill, County Cork, Ireland March 28, 2025. REUTERS/Clodagh Kilcoyne

AbbVie Inc. agreed to pay up to $2.54B to develop cancer treatments with Disco Pharmaceuticals, marking an early-stage push into next-generation bispecific therapies. The deal highlights surging pharmaceutical interest in precision oncology treatments designed to minimize damage to healthy tissue. Bispecific antibodies have attracted major investments from drugmakers including Bristol-Myers Squibb Co. and Pfizer Inc. amid rising competition in oncology.